| Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. | |
| | |
MedLine Citation:
|
PMID: 21498063 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: Indacaterol is a novel, inhaled, once-daily ultra long-acting β(2)-agonist (ultra-LABA) for the treatment of COPD. This study investigated the effect of indacaterol on exercise endurance, and on lung hyperinflation during exercise and at rest in patients with moderate-to-severe COPD. METHODS: In this double-blind, placebo-controlled, two-period crossover study (3-week treatment, 3-week washout between treatments), patients were randomized to receive indacaterol 300 μg once-daily or matching placebo. The primary efficacy variable was exercise endurance time after 3 weeks of treatment, measured through constant-load cycle ergometry testing performed at 75% of the peak work rate in a screening incremental exercise test. RESULTS: Of 90 patients randomized (mean age: 62.8 years; post-bronchodilator FEV(1): 61.2% predicted and FEV(1)/FVC: 51.6%), 74 completed the study. Pre-treatment exercise tolerance averaged 459 s. Improvement in exercise endurance time was higher with indacaterol 300 μg than with placebo both after the first dose (treatment difference: 101 s; p < 0.001) and after 3 weeks (treatment difference: 111 s; p = 0.011). In addition, indacaterol increased end-exercise inspiratory capacity (IC) versus placebo after 3 weeks (0.28 L, p = 0.002). Significant improvements were also observed in resting IC (0.17 L, p = 0.001), FEV(1) (0.25 L, p < 0.001) and FVC (0.26 L, p < 0.001) with indacaterol compared with placebo at 75 min post-dose after 3 weeks. CONCLUSION: In conclusion, indacaterol treatment improved the ability of patients with COPD to exercise. In addition, the improvements observed in resting and end-exercise IC indicate reductions in lung hyperinflation after 3 weeks treatment (ClinicalTrials.gov registration number: NCT00620022). |
| | |
Authors:
|
Denis E O'Donnell; Richard Casaburi; Walter Vincken; Luis Puente-Maestu; James Swales; David Lawrence; Benjamin Kramer; |
Related Documents
:
|
21347523 - Predictors of adherence to an exercise program for shoulder pain and dysfunction in hea... 15612533 - The role of peripheral chemoreceptor activity on the respiratory responses to hypoxia a... 16691513 - The development of endothermy during pouch life in the eastern barred bandicoot (perame... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-4-15 |
Journal Detail:
|
Title: Respiratory medicine Volume: - ISSN: 1532-3064 ISO Abbreviation: - Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-4-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8908438 Medline TA: Respir Med Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Queen's University and Kingston General Hospital, Kingston, Ontario K7L 2V7, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Preincisional local infiltration of tramadol at the trocar site versus intravenous tramadol for pain...
Next Document: An ecological perspective of microbial secondary metabolism.